Moreover, an increasing number of available molecules have been tested in patients with RA [1], resulting in a broad therapeutic armamentarium and better outcomes especially when autoantibodies, such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA), are present [2]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.